UM Miller School of Medicine: Clinical Trial Forges New Standard of Care for Advanced Hodgkin Lymphoma
November 05, 2024
November 05, 2024
MIAMI, Florida, Nov. 5 (TNSres) -- The University of Miami Miller School of Medicine issued the following news:
By Charlotte Schubert
Adding the immunotherapy drug nivolumab to a mix of chemotherapy drugs outperformed the current standard therapy for advanced Hodgkin lymphoma in a large clinical trial.
The new study is rapidly changing how patients are being treated internationally and at Sylvester Comprehensive Cancer Center, part of the University of Miam . . .
By Charlotte Schubert
Adding the immunotherapy drug nivolumab to a mix of chemotherapy drugs outperformed the current standard therapy for advanced Hodgkin lymphoma in a large clinical trial.
The new study is rapidly changing how patients are being treated internationally and at Sylvester Comprehensive Cancer Center, part of the University of Miam . . .